



General Assembly

Substitute Bill No. 446

February Session, 2006

* _____SB00446PH_INS031306_____*

**AN ACT MANDATING HEALTH INSURANCE COVERAGE FOR
PHOSPHODIESTERASE TYPE FIVE INHIBITORS FOR MEN
DIAGNOSED WITH PROSTATE CANCER.**

Be it enacted by the Senate and House of Representatives in General Assembly convened:

1 Section 1. Section 38a-492g of the general statutes is repealed and
2 the following is substituted in lieu thereof (*Effective October 1, 2006*):

3 (a) Each individual health insurance policy providing coverage of
4 the type specified in subdivisions (1), (2), (4), (11) and (12) of section
5 38a-469 delivered, issued for delivery, renewed or continued in this
6 state on or after January 1, 2000, shall provide coverage for laboratory
7 and diagnostic tests, including, but not limited to, prostate specific
8 antigen (PSA) tests, to screen for prostate cancer for men who are
9 symptomatic, whose biological father or brother has been diagnosed
10 with prostate cancer, and for all men fifty years of age or older.

11 (b) Each individual health insurance policy providing coverage of
12 the type specified in subdivisions (1), (2), (4), (11) and (12) of section
13 38a-469 delivered, issued for delivery, amended, renewed or continued
14 in this state on or after October 1, 2006, that provides coverage for
15 outpatient prescription drugs approved by the federal Food and Drug
16 Administration shall not exclude coverage for up to twenty tablets per
17 month of phosphodiesterase type five inhibitors for the therapeutic
18 treatment of prostate cancer, for a period of two years or less, for any

19 male who has been diagnosed with, and received treatment for,
 20 prostate cancer.

21 Sec. 2. Section 38a-518g of the general statutes is repealed and the
 22 following is substituted in lieu thereof (*Effective October 1, 2006*):

23 (a) Each group health insurance policy providing coverage of the
 24 type specified in subdivisions (1), (2), (4), (11) and (12) of section 38a-
 25 469 delivered, issued for delivery, renewed or continued in this state
 26 on or after January 1, 2000, shall provide coverage for laboratory and
 27 diagnostic tests, including, but not limited to, prostate specific antigen
 28 (PSA) tests, to screen for prostate cancer for men who are
 29 symptomatic, whose biological father or brother has been diagnosed
 30 with prostate cancer, and for all men fifty years of age or older.

31 (b) Each group health insurance policy providing coverage of the
 32 type specified in subdivisions (1), (2), (4), (11) and (12) of section 38a-
 33 469 delivered, issued for delivery, amended, renewed or continued in
 34 this state on or after October 1, 2006, that provides coverage for
 35 outpatient prescription drugs approved by the federal Food and Drug
 36 Administration shall not exclude coverage for up to twenty tablets per
 37 month of phosphodiesterase type five inhibitors for the therapeutic
 38 treatment of prostate cancer, for a period of two years or less, for any
 39 male who has been diagnosed with, and received treatment for,
 40 prostate cancer.

This act shall take effect as follows and shall amend the following sections:

Section 1	<i>October 1, 2006</i>	38a-492g
Sec. 2	<i>October 1, 2006</i>	38a-518g

PH

Joint Favorable Subst. C/R

INS